The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Journal of the American College of Cardiololgy

21 July Jul 2017 2 months ago
  • Salvioni A

GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non-vitamin K antagonist oral anticoagulant (NOAC), became available.

This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1.

Reference

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Bartels DB, Lip GY; GLORIA-AF Investigators. Salvioni A among collaborators. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2. J Am Coll Cardiol 2017;69(7):777-785. Go to PubMed